ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT)
Clinical trials for ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) explained in plain language.
Never miss a new study
Get alerted when new ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) trials appear
Sign up with your email to follow new studies for ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for AML patients: targeted drug may outperform standard care after transplant
Disease control Recruiting nowThis study tests whether the drug gilteritinib works better than sorafenib at keeping leukemia from coming back in people with a specific genetic mutation (FLT3-ITD) after a stem cell transplant. About 594 participants will be randomly assigned to take one of the two drugs for up…
Matched conditions: ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT)
Phase: PHASE3 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated May 17, 2026 11:36 UTC
-
New hope for High-Risk leukemia: Post-Transplant pill aims to keep cancer away
Disease control Recruiting nowThis study tests whether a drug called chidamide can help prevent relapse in people with high-risk acute myeloid leukemia (AML) after a stem cell transplant. About 134 adults aged 18-75 who are in remission after transplant will either receive chidamide or be observed. The goal i…
Matched conditions: ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT)
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 12, 2026 13:41 UTC